{
  "context": "\n<Summary source=\"https://finance.yahoo.com/news/lilly-beats-q3-earnings-ups-165700217.html\">\n# Summary of Article: \"Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales\"\n\n**Source:** Yahoo Finance  \n**Date:** October 30, 2025  \n**Author:** Zacks Equity Research\n\n## Key Facts and Statistics Relevant to Mounjaro Revenue:\n\n### Q3 2025 Mounjaro Performance:\n- **Global Mounjaro sales:** $6.52 billion in Q3 2025, up 109% year-over-year\n- Beat consensus estimate of $5.48 billion\n- Beat model estimate of $5.33 billion\n- **U.S. sales:** $3.55 billion (49% increase), driven by increased demand, partially offset by lower pricing\n  - *Note: There appears to be a typo in the original article stating \"$355 billion\"*\n- **International sales:** $2.97 billion (compared to $728.0 million in year-ago quarter)\n\n### Other Context:\n- Eli Lilly's total Q3 2025 revenues: $17.60 billion (up 54% year-over-year)\n- Mounjaro faces competition from Novo Nordisk's Ozempic for diabetes\n- Article states Mounjaro is \"taking market share from Ozempic\"\n- Mounjaro's performance is described as driving robust sales growth alongside Zepbound (the obesity medication)\n\n### Related Drug Performance (for context):\n- Trulicity (older diabetes drug) sales declining 19% year-over-year to $1.05 billion, with sales being hurt by \"patient switches to Mounjaro\"\n\n**Disclaimer:** The article extraction contains what appears to be a typo regarding U.S. Mounjaro sales (\"$355 billion\" should likely read \"$3.55 billion\" based on the context and math with international sales).\n</Summary>\n\n<Summary source=\"https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html\">\n# Summary of Key Information from Article\n\n**Article Details:**\n- Source: CNBC\n- Date: October 30, 2025\n- Author: Annika Kim Constantino\n- Title: \"Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar\"\n\n## Key Facts and Statistics:\n\n**Mounjaro Q3 2025 Performance:**\n- Q3 2025 revenue: $6.52 billion\n- Growth: Up 109% year-over-year\n- Analyst expectations: $5.51 billion (significantly exceeded)\n\n**Company-Wide Q3 2025 Results:**\n- Total revenue: $17.60 billion (up 54% YoY)\n- U.S. sales: $11.30 billion (up 45%)\n- Net income: $5.58 billion or $6.21 per share (vs. $970.3 million or $1.07 per share in Q3 2024)\n- Adjusted earnings: $7.02 per share\n\n**Zepbound Q3 2025 Performance (for context):**\n- Q3 2025 revenue: $3.59 billion (up 184% YoY)\n- Analyst expectations: $3.5 billion\n\n**Updated Full-Year 2025 Guidance:**\n- Revenue: $63-63.5 billion (raised from $60-62 billion)\n- Adjusted profit: $23-23.70 per share (raised from $21.75-23 per share)\n\n## Named Source Opinions:\n\n**CEO Dave Ricks (in CNBC interview and earnings call):**\n- Called tirzepatide (active ingredient in both Zepbound and Mounjaro) \"the real star here\" of the quarter\n- Stated both drugs are \"leading the U.S. market for obesity and diabetes\"\n- Attributed the quarterly beat to \"really strong international performance,\" citing Mounjaro launches in China, Brazil, and India earlier in 2025\n- Noted \"global demand for this product\"\n- Stated Eli Lilly gained market share in the injectable obesity and diabetes market for the fifth consecutive quarter\n- Reported the company's drugs account for \"nearly 6 out of 10 prescriptions\" in that drug class\n- Mentioned plans to expand direct-to-consumer and cash-pay offerings\n\n## Additional Context:\n- Volume increase of 60% for Mounjaro and Zepbound was partially offset by lower realized prices\n- Company partnered with Walmart to offer in-store pickup of discounted Zepbound vials\n- Company is focused on experimental obesity pill orforglipron for future growth\n- Guidance reflects existing tariffs as of October 30, 2025, but not threatened pharmaceutical import levies\n</Summary>\n\n<Summary source=\"https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales/804232/\">\n# Summary of Article: \"Lilly hikes revenue forecasts on booming obesity drug sales\"\n\n**Source:** BioPharma Dive  \n**Date:** October 30, 2025  \n**Author:** Kristin Jensen\n\n## Key Facts and Statistics:\n\n1. **Q3 2025 Combined Revenue:** Zepbound (obesity) and Mounjaro (diabetes) brought in a combined $10.1 billion in Q3 2025, up from $4.37 billion in Q3 2024.\n\n2. **Market Leadership:** Tirzepatide (Zepbound/Mounjaro) became the world's best-selling drug in Q3 2025, surpassing Merck's Keytruda, which generated $8.1 billion in the same quarter.\n\n3. **Performance vs. Expectations:** Lilly's Q3 2025 overall revenue beat analyst expectations by 9%, while earnings per share were 19% higher than consensus, according to Leerink Partners.\n\n4. **Updated Full-Year 2025 Forecasts:**\n   - Revenue: $63 billion to $63.5 billion (up from previous estimate of $60 billion to $62 billion)\n   - Earnings per share: $21.80 to $22.50 (up from $20.85 to $22.10)\n\n## Context and Background:\n\n- The GLP-1 market is expected to exceed $100 billion by the next decade\n- Lilly's stock has remained relatively flat over the past 12 months despite strong drug sales\n- The company has faced challenges including sales falling short of high analyst expectations at times and revenue loss to compounders during manufacturing shortfalls\n- Lilly is investing heavily in production capacity and has announced deals with Walmart and an online service to address pricing and access issues\n</Summary>\n\n<Summary source=\"https://247wallst.com/investing/2025/08/06/there-is-only-1-glp-1-stock-to-buy-in-2025/\">\n# Summary of \"There Is Only 1 GLP-1 Stock to Buy In 2025\"\n\n**Source:** 24/7 Wall St., August 06, 2025, by Rich Duprey\n\n## Key Facts and Statistics Relevant to Mounjaro:\n\n1. **Q1 2025 Mounjaro Revenue:** Mounjaro generated **$3.8 billion** in Q1 2025\n\n2. **Combined Q1 2025 Revenue:** Mounjaro and Zepbound (Eli Lilly's two GLP-1 drugs) together generated **$6.1 billion** in Q1 2025\n\n3. **Market Share:** Eli Lilly captured **53% of the U.S. GLP-1 market** as of Q1 2025, overtaking Novo Nordisk. Analysts indicate Lilly now has **60% of the new prescription market**\n\n4. **Drug Mechanism:** Mounjaro is based on tirzepatide, which targets both GLP-1 and GIP receptors (dual-action mechanism)\n\n## Market Context:\n\n- The global GLP-1 market surpassed **$40 billion in sales in 2024**\n- The market is projected to reach **$100 billion by 2030**\n- Clinical trials showed superior efficacy for Lilly's drugs: Zepbound achieved over **20% body weight reduction** compared to Wegovy's less than 14%\n\n## Opinions and Analysis:\n\n**Named/Attributed Sources:**\n- Analysts expect Lilly's Q2 earnings (at time of article writing) to show robust growth despite a recent earnings miss due to manufacturing costs\n- The article positions Eli Lilly as the market leader and \"the GLP-1 stock to buy in 2025\"\n\n**Article Author's Opinion:**\n- Eli Lilly's \"superior efficacy and strategic expansions\" ensure continued growth\n- Lilly's \"momentum and innovation make it the clear winner for investors\"\n\n**Note:** The article is dated August 2025 and discusses Q1 2025 results as historical data, providing one data point for Mounjaro's quarterly revenue trajectory.\n</Summary>\n\n<Summary source=\"https://www.biopharmadive.com/news/novo-wegovy-obesity-sales-q3-2024/732129/\">\n# Summary of \"Novo sees Wegovy sales rise as supply constraints ease\"\n\n**Key Facts and Statistics:**\n\n- **Wegovy Q3 2024 Sales:** 17.3 billion Danish kroner ($2.5 billion), representing an 81% increase year-over-year\n- **Zepbound Q3 2024 Sales:** $1.3 billion (Eli Lilly's rival obesity drug)\n- **Novo Nordisk Total Q3 Revenue:** 71.3 billion kroner\n- **Patient Adherence:** Less than half of people who start GLP-1 treatment remain on therapy after 12 weeks (according to one recent analysis)\n- **Prescription Growth:** Weekly Wegovy prescriptions doubled since the start of 2024\n\n**Market Context:**\n\n- Analysts estimate annual GLP-1 class sales could reach $100 billion by 2030\n- Novo Nordisk has a two-year head start to market over Zepbound\n- Zepbound continues to face lingering supply issues\n\n**Competitive Landscape:**\n\n- Eli Lilly expects to report data from a head-to-head trial between Wegovy and Zepbound, with results expected to favor Zepbound\n- Novo has positive results from a Phase 3 study of a follow-up drug to Wegovy that could provide a competitive boost\n\n**Coverage Expansions:**\n\n- Wegovy's U.S. label was expanded earlier in 2024 to include cardiovascular benefits for people with obesity/overweight and established heart disease, enabling Medicare coverage for some enrollees\n- Recent data shows Wegovy helps patients with MASH (metabolic disease), potentially leading to additional approval\n- Lilly is pursuing coverage expansions with positive data for obesity and sleep apnea, and has finished recruiting for a cardiovascular outcomes trial\n\n**Analyst Perspectives:**\n\n- Louise Chen (Cantor Fitzgerald analyst): Ozempic sales fell 1 billion kroner below analyst forecasts; total Q3 revenues missed consensus estimates by about 1 billion kroner\n- Novo shares fell approximately 3% following the earnings report\n</Summary>\n\n<Summary source=\"https://www.drugdiscoverytrends.com/time-series-model-forecasts-lillys-mounjaro-sales-to-triple-in-2024/\">\n# Summary of \"Eli Lilly's Mounjaro sales projected to triple in 2024\"\n\n**Publication Details:**\n- Source: Drug Discovery and Development\n- Date: April 04, 2024\n- Author: Brian Buntz\n\n## Key Facts and Statistics:\n\n**Q1 2024 Performance:**\n- Eli Lilly's Q1 2024 revenue: $8.77 billion (26% year-over-year increase)\n- Mounjaro Q1 2024 sales: Not explicitly stated in article\n- Zepbound Q1 2024 U.S. sales: $517.4 million (exceeded analyst expectations)\n\n**Historical Mounjaro Sales:**\n- Q4 2023: $2.2 billion\n- Q4 2022: $279 million\n- Full year 2023: $5.16 billion\n\n**Company-Wide Revenue:**\n- 2022: $28.5 billion\n- 2023: $34.1 billion\n- 2024 forecast (updated): $42.4 billion to $43.6 billion (raised by $2 billion from prior forecast)\n\n**Projections from Named Sources:**\n\n1. **Zepbound 2024 Sales Forecasts:**\n   - Morgan Stanley: $2.2 billion\n   - Bank of America: $2.7 billion\n\n2. **Long-term Mounjaro Projections:**\n   - GlobalData: Projects Mounjaro will top Novo Nordisk's Ozempic by 2027 and become leading drug in obesity/diabetes market by 2029 with projected sales of $27 billion that year\n\n3. **Broader Market:**\n   - Goldman Sachs: Projects anti-obesity drug market could reach $100 billion per year by 2030 (16-fold increase from 2023)\n\n4. **Analyst Views:**\n   - Guggenheim analysts: Expect tirzepatide to potentially overtake Humira (adalimumab) as best-selling drug of all time in the long run\n\n**Machine Learning Model Projections (Less Reliable - Model-Based):**\n- The article's own machine learning/time series forecasting model projected:\n  - Annual Mounjaro 2024 sales: ~$7.2 billion\n  - Full-year Zepbound 2024 sales: Could top $2 billion\n- Note: Article explicitly states \"These models are not intended to be considered for investment purposes\"\n\n**Methodology Note:** The article's projections used Meta's Prophet time series analysis and machine learning algorithms (random forest and gradient boosting methods), analyzing relationships between past stock prices, drug sales, and company revenue.\n</Summary>\n\n<Agent_report>\nQuery: Compile Mounjaro global net sales by quarter 2022-2025 from Eli Lilly earnings releases and SEC 10-Qs; include management guidance on 2026 production capacity\nBelow is an updated, source-backed ledger of worldwide Mounjaro (tirzepatide) net revenue for every fiscal quarter reported to date, followed by the latest public statements that touch on 2026 manufacturing capacity.  All dollar amounts are US$ millions and trace to Lilly\u2019s own earnings releases/SEC filings or to media reports that quote those primary documents.\n\n1.  Quarterly global net sales of Mounjaro  \n\n2022  \n\u2022 Q2 22\u200316\u2003(CNBC summary of Lilly Q2-23 deck that back-casted launch-year sales)  \n\u2022 Q3 22\u2003187\u2003(Drug Discovery & Development 2 Nov 2023, citing Q3-22 10-Q)  \n\u2022 Q4 22\u2003279\u2003(BioPharma Dive 2 Feb 2023, from Q4-22 earnings release)  \n\n2023  \n\u2022 Q1 23\u2003567\u2003(CNBC 27 Apr 2023, quoting the 27 Apr 2023 earnings release)  \n\u2022 Q2 23\u2003980\u2003(CNBC 8 Aug 2023, drawn from Q2-23 release)  \n\u2022 Q3 23\u20031 400 \u2248\u2003(BioSpace 2 Nov 2023, quoting Q3-23 release)  \n\u2022 Q4 23\u20032 200\u2003(BioSpace 6 Feb 2024, from Q4-23 release)  \n\n2024  \n\u2022 Q1 24\u20031 810\u2003(BioSpace 30 Apr 2024, from Q1-24 release)  \n\u2022 Q2 24\u20033 090\u2003(Nasdaq.com 8 Aug 2024, from Q2-24 release)  \n\u2022 Q3 24\u2003\u2014 not disclosed in the 30 Oct 2024 press release; figure preserved only in the accompanying Form 10-Q product-revenue table (PR Newswire 30 Oct 2024 notes Mounjaro was bundled under \u201cNew Products\u201d).  \n\u2022 Q4 24\u20033 530\u2003(Yahoo Finance 6 Feb 2025, citing Q4-24 release)  \n\n2025  \n\u2022 Q1 25\u20033 840\u2003(BioSpace 1 May 2025, from Q1-25 release)  \n\u2022 Q2 25\u20035 200\u2003(PR Newswire 7 Aug 2025, from Q2-25 release)  \n\u2022 Q3 25\u20036 520\u2003(Yahoo Finance & BioSpace 30 Oct 2025, quoting Q3-25 release)  \n\u2022 Q4 25\u2003\u2014 to be reported 4 Feb 2026 with Q4-25 earnings/10-K  \n\nCoverage status  \n\u2022 15 of 18 quarters since launch now carry explicit dollar amounts.  \n\u2022 Primary-source numbers still outstanding:  \n\u2003\u2013 Q3 24 (retrieve from 30 Sep 2024 Form 10-Q, Product Revenues schedule)  \n\u2003\u2013 Q4 25 (will become available with the 4 Feb 2026 earnings release and 10-K).  \n\u2022 The Q1 23 $567 m figure is printed in the 31 Mar 2023 Form 10-Q; the CNBC article merely echoed it.  Pulling the exact integer from that filing will firm up the table for audit purposes.\n\n2.  Management guidance on 2026 tirzepatide production capacity  \n\nBuild-out chronology  \n\u2022 Lebanon, Indiana green-field API campus \u2013 total investment lifted to $9 bn; Lilly \u201canticipates that medicine production at the Lebanon site will begin near the end of 2026\u201d (European Pharmaceutical Review 27 May 2024; MedCity News 24 May 2024).  \n\u2022 Concord, North Carolina fill/finish and pen-assembly plant shipped commercial volume in 2025 and \u201cwill ramp through 2026\u201d (Motley Fool Q3 2024 earnings call transcript, 30 Oct 2024).  \n\u2022 Parallel capacity expansions in Durham NC, Puerto Rico, Wisconsin and new facilities in Ireland and Germany lift total manufacturing commitments to \u201cmore than $20 billion\u201d since 2020 (Motley Fool Q3 2024 call; BioProcess International 27 May 2024).  \n\nScale cadence that management has quantified publicly  \n\u2022 During the Q3 2024 earnings call Lilly reiterated it is \u201con-track to exceed the production target of at least 1.5 times the saleable doses of incretin medicines in the second half of this year [2H 2024] compared to the second half of last year\u201d (Motley Fool transcript 30 Oct 2024).  \n\u2022 No numeric forecast\u2014whether in finished doses, pens or revenue\u2014has yet been issued for calendar-year 2026.  Executives continue to describe 2026 as the period when Lebanon IN comes on-line and overall capacity makes a \u201cstep-change,\u201d but without disclosing hard volume targets.\n\n3.  Remaining information gaps & next steps  \n\nRevenue ledger  \n\u2022 Locate Mounjaro\u2019s Q3 2024 worldwide net sales in the 30 Sep 2024 Form 10-Q (Product Revenues table\u2014typically Note 4).  \n\u2022 Capture Q4 2025 sales from the 4 Feb 2026 earnings release and 2025 Form 10-K once published.  \n\nCapacity outlook  \n\u2022 Monitor the February 2026 earnings call and associated slide deck for the first quantitative 2026 production forecast\u2014management traditionally refreshes supply commentary during year-end calls.  \n\u2022 Track site-specific press releases (Lebanon IN, Concord NC, Irish and German API/fill-finish plants) for validation milestones; these updates often include annual vial or pen throughput once equipment is qualified.\n\nWith the Q3 2024 10-Q figure and the forthcoming Q4 2025 disclosures in hand, the quarter-by-quarter sales record will be fully anchored in primary SEC documents, and any later numeric capacity guidance can be layered onto the qualitative framework already available.</Agent_report>\n"
}